Bjerrum L, Søgaard J, Hallas J, Kragstrup J
Syddansk Universitet, Odense.
Ugeskr Laeger. 2000 Apr 3;162(14):2037-40.
Polypharmacy, the simultaneous use of multiple drugs, is associated with adverse drug reactions, medication errors, and increased risk of hospitalisation. When the number of drugs is five or more (major polypharmacy), a significant risk may be present. We analysed the prevalence of major polypharmacy among listed patients, and identified possible predictors of major polypharmacy related to the practice. Prescription data were retrieved from the Odense Pharmaco-epidemiological Database and the age and sex standardised prevalence rate of major polypharmacy was calculated for each practice (n = 173). Possible predictors of major polypharmacy related to the GPs were analysed by backward stepwise linear multiple regression. A six-fold variation between practices in the prevalence of major polypharmacy was found, i.e. from 16 to 96 per 1000 listed patients (median: 42). Predictors related to the practice structure, workload, clinical work profile, and prescribing profile could explain 56% of the variation.
多重用药，即同时使用多种药物，与药物不良反应、用药错误以及住院风险增加有关。当药物数量为五种或更多（重度多重用药）时，可能存在重大风险。我们分析了在册患者中重度多重用药的患病率，并确定了与该做法相关的重度多重用药的可能预测因素。处方数据取自欧登塞药物流行病学数据库，并计算了每种医疗行为（n = 173）的年龄和性别标准化重度多重用药患病率。通过向后逐步线性多元回归分析了与全科医生相关的重度多重用药的可能预测因素。发现不同医疗行为之间重度多重用药患病率存在六倍差异，即每1000名在册患者中从16例到96例（中位数：42例）。与医疗行为结构、工作量、临床工作概况和处方概况相关的预测因素可以解释56%的差异。
